- Home
- INVA
INVA
Innoviva Inc.
as 12-18-2024 11:38am EST
Innoviva Inc is a company with a portfolio of royalties and innovative healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | BURLINGAME |
| Market Cap: | 1.2B | IPO Year: | 2004 |
| Target Price: | N/A | AVG Volume (30 days): | 684.8K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.99 | EPS Growth: | 46.55 |
| 52 Week Low/High: | $14.33 - $21.28 | Next Earning Date: | 11-06-2024 |
| Revenue: | $352,745,000 | Revenue Growth: | 21.46% |
| Revenue Growth (this year): | 16.2% | Revenue Growth (next year): | -0.18% |
Latest Innoviva Inc. News
INVA Breaking Stock News: Dive into INVA Ticker-Specific Updates for Smart Investing
TipRanks
a day ago
Innoviva enters distribution, license agreement with Basilea for Zevtera
MT Newswires
2 days ago
Innoviva to Sell Basilea Pharmaceutica's MRSA Antibiotic Zevtera in US Under Exclusive Deal
Business Wire
2 days ago
Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)
Argus Research
8 days ago
INVA: What does Argus have to say about INVA?
Argus Research
15 days ago
INVA: What does Argus have to say about INVA?
Argus Research
22 days ago
INVA: What does Argus have to say about INVA?
Business Wire
22 days ago
Innoviva to Participate in the Citi 2024 Global Healthcare Conference
PR Newswire
a month ago
Two In Vitro Studies on Eravacycline (XERAVA®) Presented at IDWeek, Demonstrating Its Sustained and Robust Antimicrobial Activity
Compare INVA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INVA Innoviva Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.